ES2059588T3 - Factor xiii para la prevencion de una hemorragia intraventricular. - Google Patents

Factor xiii para la prevencion de una hemorragia intraventricular.

Info

Publication number
ES2059588T3
ES2059588T3 ES89102471T ES89102471T ES2059588T3 ES 2059588 T3 ES2059588 T3 ES 2059588T3 ES 89102471 T ES89102471 T ES 89102471T ES 89102471 T ES89102471 T ES 89102471T ES 2059588 T3 ES2059588 T3 ES 2059588T3
Authority
ES
Spain
Prior art keywords
prevention
factor xiii
intraventricular hemorrhage
intraventricular
hemorrhage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES89102471T
Other languages
English (en)
Spanish (es)
Inventor
Akira Shirahata
Minoru Uchida
Satoshi Tanaka
Kenichiro Tsumura
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis KK
Original Assignee
Hoechst Japan Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst Japan Ltd filed Critical Hoechst Japan Ltd
Application granted granted Critical
Publication of ES2059588T3 publication Critical patent/ES2059588T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
ES89102471T 1988-02-24 1989-02-14 Factor xiii para la prevencion de una hemorragia intraventricular. Expired - Lifetime ES2059588T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP63039646A JPH01216939A (ja) 1988-02-24 1988-02-24 末熟児頭蓋内出血阻止剤

Publications (1)

Publication Number Publication Date
ES2059588T3 true ES2059588T3 (es) 1994-11-16

Family

ID=12558846

Family Applications (1)

Application Number Title Priority Date Filing Date
ES89102471T Expired - Lifetime ES2059588T3 (es) 1988-02-24 1989-02-14 Factor xiii para la prevencion de una hemorragia intraventricular.

Country Status (12)

Country Link
US (1) US5114916A (show.php)
EP (1) EP0330049B1 (show.php)
JP (1) JPH01216939A (show.php)
KR (1) KR0137476B1 (show.php)
AT (1) ATE94070T1 (show.php)
AU (1) AU613154B2 (show.php)
CA (1) CA1332352C (show.php)
DE (1) DE68908913T2 (show.php)
DK (1) DK174978B1 (show.php)
ES (1) ES2059588T3 (show.php)
IE (1) IE63656B1 (show.php)
PT (1) PT89802B (show.php)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612456A (en) * 1988-11-14 1997-03-18 Zymogenetics, Inc. Factor XIII compositions
WO1993012813A1 (en) * 1991-12-31 1993-07-08 Zymogenetics, Inc. Methods and compositions for reducing blood loss
WO1993020837A1 (fr) * 1992-04-21 1993-10-28 Ajinomoto Co., Inc. Remede contre les plaies
CA2149209C (en) * 1992-11-12 2000-08-01 Martin William Edwards Use of topically applied factor xiii for inhibiting hemorrhage
JPH07328108A (ja) * 1994-06-10 1995-12-19 Ajinomoto Co Inc 生体組織接着剤及び血液凝固剤
ES2245114T3 (es) 1998-08-06 2005-12-16 Mountain View Pharmaceuticals, Inc. Conjugados de peg-oxidasa de urato y su uso.
JP2008510476A (ja) * 2004-08-27 2008-04-10 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 生物学的材料からのｘｉｉｉ因子ポリペプチドの精製
ATE540974T1 (de) * 2004-11-23 2012-01-15 Zymogenetics Inc Reinigung des rekombinanten menschlichen faktors xiii
TWI418564B (zh) * 2005-04-11 2013-12-11 Savient Pharmaceuticals Inc 利用陽離子界面活性劑之蛋白質純化
EP1871874B1 (en) 2005-04-11 2015-04-08 Crealta Pharmaceuticals LLC Variant forms of urate oxidase and use thereof
EP2013225B1 (en) * 2006-04-12 2014-12-17 Crealta Pharmaceuticals LLC Purification of proteins with cationic surfactant
EP2446260B1 (en) 2009-06-25 2018-12-26 Horizon Pharma Rheumatology LLC Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
WO2018089808A1 (en) 2016-11-11 2018-05-17 Horizon Pharma Rheumatology Llc Combination therapies of prednisone and uricase molecules and uses thereof
WO2020160325A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Reducing immunogenicity to pegloticase
WO2020160322A1 (en) 2019-01-30 2020-08-06 Horizon Pharma Rheumatology Llc Tolerization reduces intolerance to pegloticase and prolongs the urate lowering effect (triple)
US12269875B2 (en) 2023-08-03 2025-04-08 Jeff R. Peterson Gout flare prevention methods using IL-1BETA blockers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3717708A (en) * 1968-10-24 1973-02-20 Cutter Lab Blood coagulation complex
DE2063070C3 (de) * 1970-12-22 1975-07-24 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung eines Arzneimittels mit fibrinstabilisierender Wirkung
DE3622642A1 (de) * 1986-07-05 1988-01-14 Behringwerke Ag Einkomponenten-gewebekleber sowie verfahren zu seiner herstellung
ATE121776T1 (de) * 1986-09-19 1995-05-15 Zymogenetics Inc Expression des biologisch aktiven faktors xiii.

Also Published As

Publication number Publication date
IE890580L (en) 1989-08-24
KR0137476B1 (ko) 1998-06-01
AU3024389A (en) 1989-08-24
PT89802A (pt) 1989-10-04
EP0330049B1 (en) 1993-09-08
KR890012659A (ko) 1989-09-18
DK174978B1 (da) 2004-04-05
JPH01216939A (ja) 1989-08-30
EP0330049A3 (en) 1991-01-30
DE68908913T2 (de) 1994-01-27
JPH0378850B2 (show.php) 1991-12-17
EP0330049A2 (en) 1989-08-30
DK83889A (da) 1989-08-25
AU613154B2 (en) 1991-07-25
DK83889D0 (da) 1989-02-23
DE68908913D1 (de) 1993-10-14
ATE94070T1 (de) 1993-09-15
CA1332352C (en) 1994-10-11
IE63656B1 (en) 1995-05-31
PT89802B (pt) 1994-04-29
US5114916A (en) 1992-05-19

Similar Documents

Publication Publication Date Title
ES2059588T3 (es) Factor xiii para la prevencion de una hemorragia intraventricular.
ATE77557T1 (de) Zusammensetzung zur erhoehung der intrazell-atpspiegel und des physischen leistungsniveaus und zur erhoehung der geschwindigkeit von wundenheilung.
ATE163849T1 (de) Arzneimittel enthaltend als wirkstoff r-alpha- liponsäure oder s-alpha-liponsäure
NO875299D0 (no) Insulinpreparat for ikke-paranteral administrasjon.
NO870241L (no) Hypoglykemiske tiazolidindioner.
ATE103914T1 (de) Neue thienylcarbonsaeureester von aminoalkoholen, ihre quaternierungsprodukte sowie die herstellung und verwendung dieser verbindungen.
DE69327432D1 (de) Heilmittel für wunden und hämorrhoiden
ATE71291T1 (de) Pharmazeutische zubereitung mit verzoegerter freigabe.
ES2073425T3 (es) Una nueva glicoproteina de tipo trombomodulina susceptible de ser obtenida a partir de la orina.
ATA91797A (de) Eine das vwf-propeptid enthaltende pharmazeutische präparation
PT87523A (pt) Mischkristalle aus insulin und insulinderivaten verfahren zur herstellung dieser mischkristalle diese mischkristalle enthaltende pharmazeutische mittel und ihre verwendung zur behandlung von diabetes mellitus
DE69133077D1 (de) Herstellung von ST1435 enthaltenden pharmazeutischen Zusammensetzungen zur topischen Verwendung
ATE5256T1 (de) Phenylpiperazinderivate von 1,3,4oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel.
DE69032000D1 (de) Behandlung kardialer Dysfunktion mit 15-Ketoprostaglandinderivaten
ATE129895T1 (de) Behandlung von pulmonarer disfunktion mit 15-keto-prostaglandin-derivaten.
ATE126437T1 (de) Verwendung von depogen zur behandlung von eingeschränktem blutkreislauf.
KR910015294A (ko) 약제 조성물
DK0499679T3 (da) Terapeutisk middel til diabetisk gangræn
AU5581186A (en) Protein absorption enhancing agent
NO890261D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive tetrahydropyridin-derivater.
DK417889A (da) Anvendelse af 2-azabicyklo(2.2.2.)-carboxylsyrederivater til fremstilling af medicinske produkter til behandling af vaskulaere sygdomme
IT8721098A0 (it) Derivati della 1-benzene solfonil 2-oco 5-alchiltio pirrolidina, un loro procedimentodi preparazione e il loro impiegocome stostanze medicinali.
IT8919215A0 (it) Dispositivo per la cura chirurgica dell'ametropia.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 330049

Country of ref document: ES